Journal article
Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data
Inmaculada Hernandez, Yuting Zhang
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | ADIS INT LTD | Published : 2017
Abstract
BACKGROUND: No studies have directly compared the effectiveness and safety of dabigatran and rivaroxaban using US Medicare data. OBJECTIVE: Our objective was to compare effectiveness and safety between rivaroxaban 20 mg/dabigatran 150 mg and rivaroxaban 15 mg/dabigatran 75 mg among patients with atrial fibrillation (AF). METHODS: Using 2010-2013 US Medicare Part D data, we selected patients with AF initiating dabigatran 150/75 mg or rivaroxaban 20/15 mg between 4 November 2011 (when rivaroxaban was approved) and 31 December 2013. Our sample included 7322 patients receiving dabigatran 150 mg, 5799 patients receiving rivaroxaban 20 mg, 1818 receiving dabigatran 75 mg, and 2568 receiving rivaro..
View full abstractGrants
Awarded by Commonwealth Fund
Awarded by Agency for Healthcare Research and Quality
Awarded by National Institute of Mental Health
Funding Acknowledgements
The authors acknowledge funding from the Commonwealth Fund (Grants 20150380 and 20130660), the Agency for Healthcare Research and Quality (No. R01 HS018657), and from the National Institute of Mental Health (No. R21 MH100721). IH has received a scholarship from "La Caixa'' Foundation (Spain).